At #ObesityWeek2026, we presented new preclinical data on MBX 6180 in the poster, “Sustained Exposure of MBX 6180, a Novel Triple GLP-1/GIP/Glucagon Receptor Agonist Prodrug, in NHPs.” https://t.co/GvG2teeEDH #ObesityWeek#ObesityResearch
Today $MBX Biosciences reported financial results for the third quarter ended September 30, 2026, highlighting recent pipeline updates and corporate progress. https://t.co/AahnVoptf9
We at $MBX Biosciences are looking for passionate professionals to join our growing team. Interested in advancing scientific innovation? Explore our open roles here: https://t.co/GstHHPUXMl
$MBX Chairman & CEO Steve Hoerter and CMO Sam Azoulay, M.D., will participate in the Guggenheim Healthcare Innovation, UBS Global Biopharma and Jefferies Global Healthcare conferences in November. Access the webcast information here: https://t.co/6AbX9CYzSS
The opening of our Burlington office and lab facility in Burlington, Massachusetts marked an exciting new chapter for $MBX, creating additional space to foster scientific innovation as we advance our pipeline. Learn more about our mission: https://t.co/DEExz1AGVQ
At $MBX Biosciences, we're developing precision peptide therapies for the treatment of endocrine and metabolic diseases, and we are seeking passionate professionals to join our team. Explore open roles: https://t.co/GstHHPUXMl
Join $MBX at #ASBMR2026 in Boston on Oct. 11 (2-3:30 p.m. ET, Discovery Hall) to learn more about our investigational once-weekly PTH replacement therapy: https://t.co/y8A6qf717Q #ClinicalResearch#Endocrinology@ASBMR
Great to be part of the 2026 #HypoPARA Conference in Phoenix. Thanks to everyone who visited the $MBX table to connect with our team and to the HypoPARAthyroidism Association for hosting an impactful event.
$MBX is proud to partner with @LS_Cares Boston who is dedicated to disrupting the cycles of poverty and inequality through investments in education, economic opportunity and health equity.
Learn more about Life Science Cares Boston: https://t.co/5hWZTPhlau
Behind every new candidate is a team translating promising science into potential new therapies. Our once-monthly triple G agonist prodrug candidate is the latest example. Meet the people behind the discovery and learn more about the $MBX pipeline: https://t.co/Og8zA2oij6
Congratulations to MBX Scientific Co-Founder Richard DiMarchi, recipient of the 2026 Rolf Luft Award. One of the field's highest honors, the award recognizes his contributions to peptide chemistry and obesity and diabetes research. Learn more: https://t.co/MfH9tnkAw4
We’re looking forward to the @MorganStanley Healthcare Conference and @Stifel Virtual Cardiometabolic Forum this month where our Chairman & CEO, Steve Hoerter, and CMO, Sam Azoulay, M.D., will participate in fireside chats. Learn more: https://t.co/ue43AUx3vN
MBX Biosciences has welcomed Jeff Held as Chief Legal Officer. Jeff brings 30+ years of legal, compliance and executive leadership experience supporting innovative biotechnology and healthcare companies through key growth milestones. Read the announcement: https://t.co/Z2wROjbavm
We are proud to announce that the first patient has been dosed in the pivotal Phase 3 oPTimize trial evaluating an investigational, once-weekly PTH replacement therapy for adults with chronic #hypoparathyroidism. Learn more: https://t.co/wCwOlH2lQ4 #RareDisease#ClinicalTrials
From obesity to hypoparathyroidism, over 194M Americans live with chronic illness. MBX supports @IAmBiotech’s #FightOfOurLives campaign, highlighting the need for continued innovation to address unmet needs. Learn more: https://t.co/4IDrmrIoqh
MBX Biosciences today reported financial results for the second quarter ended June 30, 2026, highlighting recent pipeline and corporate progress. View the press release: https://t.co/qjTYDl8ydj
Looking to make an impact in biotech? At MBX Biosciences, we're advancing precision peptide therapies for obesity and hypoparathyroidism – and seeking passionate professionals to join our team. Explore our open roles: https://t.co/hZMM5k2Wu1. #Hiring#BiotechCareers#LifeSciences
By 2035, 25% of the global population is projected to have obesity. Yet, many patients discontinue current treatments within 1–2 years, underscoring the need for more options. These insights and more from MBX’s Obesity Day: https://t.co/6AbX9CY23k
We’re #Hiring! MBX is seeking talented professionals in Business Development, Finance, IT, Program Management and Regulatory to join us on our mission to advance treatments for endocrine and metabolic disorders. Explore our open roles: https://t.co/hZMM5k2Wu1.
50 years of biotech progress and just getting started. MBX is proud to support @IAmBiotech’s #FightOfOurLives campaign as we advance our PEP™ platform for rare endocrine and metabolic diseases. Explore the industry’s impact over the past 50 years: https://t.co/CkCNr4EEg5